Search research articles
Contact Us
Filters
Showing results (51-60 of 74) with videos related to
Page
of 8
Sort By:
Tobacco Control
|
September 10, 2024
Youth and young adult flavour expectancies for new 'non-menthol' cigarettes introduced following California's ban on flavoured tobacco products
Jennifer M Kreslake, Jamie Cordova, Andrew B Seidenberg, et al.
American Journal of Preventive Medicine
|
June 14, 2024
Coverage of Indoor Smoking and Vaping Restrictions in the U.S., 1990-2021
Andrew B Seidenberg, Karl Braganza, Maxwell Chomas, et al.
Tobacco Control
|
October 20, 2025
Population coverage and comprehensiveness of flavoured tobacco sales restrictions in the USA, 2010-2023
Emily M Donovan, Karl Braganza, Megan C Diaz, et al.
Tobacco Prevention & Cessation
|
August 8, 2020
Association of tobacco control policies with cigarette smoking among school youth aged 13-15 years in the Philippines, 2000-2015
René A Arrazola, Lauren M Dutra, Evelyn Twentyman, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco
|
October 4, 2023
Effects of Modified Risk Tobacco Product Claims on Consumer Responses
Andrew B Seidenberg, Marcella H Boynton, Noel T Brewer, et al.
American Journal of Orthopedics (Belle Mead, N.J.)
|
February 24, 2001
Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain
A Reicin, J Brown, M Jove, et al.
American Journal of Preventive Medicine
|
October 16, 2021
Awareness of Alcohol as a Carcinogen and Support for Alcohol Control Policies
Andrew B Seidenberg, Kara P Wiseman, Raimee H Eck, et al.
Lancet (London, England)
|
July 15, 2014
Twitter: an opportunity for public health campaigns
Mackenzie R Wehner, Mary-Margaret Chren, Melissa L Shive, et al.
Clinical Therapeutics
|
November 24, 1999
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group
T J Schnitzer, K Truitt, R Fleischmann, et al.
Tobacco Control
|
July 15, 2011
Smokers' self-reported responses to the introduction of reduced ignition propensity (RIP) cigarettes
Andrew B Seidenberg, Vaughan W Rees, Hillel R Alpert, et al.
Page
of 8
Search research articles
Search
Showing results (51-60 of 74) with videos related to
Sort By:
Page
of 8
Tobacco Control
|
September 10, 2024
Youth and young adult flavour expectancies for new 'non-menthol' cigarettes introduced following California's ban on flavoured tobacco products
Jennifer M Kreslake, Jamie Cordova, Andrew B Seidenberg, et al.
American Journal of Preventive Medicine
|
June 14, 2024
Coverage of Indoor Smoking and Vaping Restrictions in the U.S., 1990-2021
Andrew B Seidenberg, Karl Braganza, Maxwell Chomas, et al.
Tobacco Control
|
October 20, 2025
Population coverage and comprehensiveness of flavoured tobacco sales restrictions in the USA, 2010-2023
Emily M Donovan, Karl Braganza, Megan C Diaz, et al.
Tobacco Prevention & Cessation
|
August 8, 2020
Association of tobacco control policies with cigarette smoking among school youth aged 13-15 years in the Philippines, 2000-2015
René A Arrazola, Lauren M Dutra, Evelyn Twentyman, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco
|
October 4, 2023
Effects of Modified Risk Tobacco Product Claims on Consumer Responses
Andrew B Seidenberg, Marcella H Boynton, Noel T Brewer, et al.
American Journal of Orthopedics (Belle Mead, N.J.)
|
February 24, 2001
Efficacy of single-dose and multidose rofecoxib in the treatment of post-orthopedic surgery pain
A Reicin, J Brown, M Jove, et al.
American Journal of Preventive Medicine
|
October 16, 2021
Awareness of Alcohol as a Carcinogen and Support for Alcohol Control Policies
Andrew B Seidenberg, Kara P Wiseman, Raimee H Eck, et al.
Lancet (London, England)
|
July 15, 2014
Twitter: an opportunity for public health campaigns
Mackenzie R Wehner, Mary-Margaret Chren, Melissa L Shive, et al.
Clinical Therapeutics
|
November 24, 1999
The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group
T J Schnitzer, K Truitt, R Fleischmann, et al.
Tobacco Control
|
July 15, 2011
Smokers' self-reported responses to the introduction of reduced ignition propensity (RIP) cigarettes
Andrew B Seidenberg, Vaughan W Rees, Hillel R Alpert, et al.
Page
of 8